帕金森病的发病机制
帕金森病是与聚集的α-突触核蛋白沉积相关的进行性神经退行性疾病。遗传学与分子病理学研究提示,α-突触核蛋白异常聚集及病理在肠道、脑干和高级脑区之间播散可能参与疾病发生与进展。线粒体、溶酶体和内体功能异常及免疫炎症反应加速发病,目前尚无疾病修饰治疗,但为合理神经保护疗法开发奠定基础。
要点
- α-突触核蛋白异常聚集及病理在肠道、脑干和高级脑区播散可能参与帕金森病发生与进展。
- 单基因和散发性帕金森病均可见线粒体、溶酶体和内体功能异常,提示多种潜在治疗途径。
- 近期研究强调可能始于肠道的适应不良免疫和炎症反应加速帕金森病发病。
核心结论
- 目前尚无帕金森病的疾病修饰治疗,但已为开发合理的神经保护疗法奠定坚实基础,希望可阻止这一致残性神经系统疾病的进展。
研究设计与样本
- 综述,基于遗传学、分子病理学、生化研究、帕金森病患者移植神经元研究以及细胞和动物模型研究。
主要发现
- 生化研究、帕金森病患者移植神经元研究及细胞和动物模型研究提示,α-突触核蛋白异常聚集及病理在肠道、脑干和高级脑区之间播散可能参与帕金森病发生与进展。
- 在细胞水平,单基因和散发性帕金森病均可见线粒体、溶酶体和内体功能异常,提示多种潜在治疗途径。
- 近期研究还强调可能始于肠道的适应不良免疫和炎症反应加速帕金森病发病。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease have been derived from genetics and molecular pathology. Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease. At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches. Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease. Although there are currently no disease-modifying treatments for Parkinson's disease, we now have a solid basis for the development of rational neuroprotective therapies that we hope will halt the progression of this disabling neurological condition.
引用
- Morris HR, Spillantini MG, Sue CM, et al. The pathogenesis of Parkinson's disease. Lancet. 2024. PMID: 38245249. doi:10.1016/S0140-6736(23)01478-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。